$400 savings end in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
2026 Agenda: Day 1 - Monday 12 January - PT (Pacific Time, GMT-08:00)
Evolving regulatory and policy dynamics are reshaping the biopharma ecosystem—impacting approval timelines, funding pathways, and market strategy. This session brings together industry and policy experts to discuss what lies ahead for biotech companies and how to navigate change to drive innovation and growth.
The Syneos Health Dealmakers’ Intentions Study is a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. Now in its 17th year, this survey provides a unique perspective on these trends by surveying business development professionals from pharmaceutical and biotechnology companies of all sizes to create forward-looking insights based on dealmakers' general expectations for activity in the coming year. This session will discuss the results of this year’s Dealmakers’ Intentions Study, providing a prospective view of the partnering and licensing landscape for the year ahead.
Join our panel of experts as they explore the latest strategies for forging successful partnerships, structuring high-impact deals, and driving collaborative innovation in the competitive landscape.
Artificial intelligence is transforming every stage of drug discovery, from target identification to lead optimization and beyond. This session explores how AI-driven approaches are accelerating innovation, improving success rates, and opening new opportunities for investment in next-generation therapeutics.
Explore the latest breakthroughs, from AI-driven insights to cutting-edge genomics and screening technologies. Learn how these innovations are unlocking new therapeutic opportunities and shaping the next generation of precision medicine.
As blockbuster checkpoint inhibitors like Keytruda and Opdivo approach their patent cliffs, the strategic focus has shifted to what comes next. This panel will gather leaders from large pharma and innovative biotechs to discuss the new era of combination regimens. They will explore the science and strategy behind pairing established immunotherapies with next-generation modalities to create transformative outcomes for patients and drive the next wave of deal-making.